The Worldwide Non-Alcoholic Steatohepatitis Industry is Projected to Reach $15 Billion by 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type, By Application Type, By Distribution Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027” report has been added to ResearchAndMarkets.com’s offering.
The global non-alcoholic steatohepatitis (NASH) market was valued at US$1.65 billion in 2021. The market value is projected to grow to US$15.04 billion by 2027.
Non-Alcoholic Steatohepatitis (NASH) is an inflammatory liver disease associated with excessive fat accumulation in the liver (steatosis), hepatocellular ballooning, and inflammation.
Non-Alcoholic Steatohepatitis or “Silent Liver Disease” leads to scarring of the liver, a kind of liver disorder caused by long-term abuse of alcohol but mainly develops in patients who are non-alcoholic or consume very little alcohol. Non-Alcoholic steatohepatitis (NASH) is the second stage of non-alcoholic fatty liver disease (NAFLD) that has progressed to the point of liver inflammation and cell damage.
The factors such as increased investment in medical infrastructure, rising consumption of processed foods containing polyunsaturated fatty acids & fructose, increased focus on development of new drugs and many companies engaged in the launch of non-invasive diagnostic procedures, are expected to drive the overall market growth in the forecasted period. The market is anticipated to grow at a CAGR of approx. 50% during the forecasted period of 2022-2027.
Market Dynamics
Growth Driver
- Rising prevalence of Non-Alcoholic Steatohepatitis (NASH)
- Rising Cases of Associated Chronic Diseases
- Rising adoption of Sedentary Lifestyle
- Rising Health Awareness
- Urbanization
Challenges
- Absence of Low Cost and Definitive Diagnostic Methods
- Regulatory Compliance
Market Trends
- Increasing Integration of Artificial Intelligence (AI)
- Digitalization
- Increased Promotion of Pipeline Drugs
- Increasing Investment on Research and Development (R&D)
Companies Mentioned
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Siemens Healthineers AG
- AstraZeneca PLC
- Galectin Therapeutics Inc.
- GENFIT S.A.
- Madrigal Pharmaceuticals, Inc.
- Inventiva S.A.
- ONE WAY LIVER, S.L.
- Galmed Pharmaceuticals Ltd.
- Cirius Therapeutics
- Prometheus Laboratories Inc.
- BioPredictive
Market Segmentation Analysis:
- By Drug Type: The report provides the bifurcation of the market into five segments based on the drug type: vitamin e & pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc and others. In 2021, the vitamin E & pioglitazone segment held the major share of the global non-alcoholic steatohepatitis market as these two drugs are seen to be effective in improving the condition associated with NASH and with no FDA approved drugs in the market to treat NASH, these drugs are expected to be continuously demanded and recommended by medical professionals as the first line drugs for treating NASH. Elafibranor non-alcoholic steatohepatitis market is the fastest growing segment of global non-alcoholic steatohepatitis market in the forecasted period of 2023-2027 owing to positive impact of elafibranor in NASH treatment during clinical trials and drug’s capability to reduce fat substance of liver, improving the conditions caused by NASH.
- By Application Type: The report provides the bifurcation of the market into two segments based on application type: treatment and diagnosis. The non-alcoholic steatohepatitis (NASH) treatment market is both the largest and fastest growing segment of global non-alcoholic steatohepatitis (NASH) market owing to increased prevalence of NASH, expected launch of new pipeline drugs by pharmaceutical companies and development of various potential pathways for NASH treatments, including lipogenesis inhibitors, medications targeting the farnesoid X receptor axis, ASK1 inhibitors, etc.
- By Distribution Type: The report provides the bifurcation of the market into three segments based on distribution type: retail pharmacies, online pharmacies and hospital pharmacies. Retail pharmacies non-alcoholic steatohepatitis (NASH) market is the largest and fastest segment of global non-alcoholic steatohepatitis (NASH) market owing to strong presence of drug stores & retail pharmacies, more engaging patient centric services, easy accessibility in terms of more convenient locations and better drug portfolio with more thorough information about medications and health items that can be used to treat the conditions associated with NASH.
- By Region: The report provides insight into the non-alcoholic steatohepatitis (NASH) market based on the regions namely North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The North America non-alcoholic steatohepatitis market holds the largest share in global non-alcoholic steatohepatitis market owing to the rise in number of cases of associated chronic diseases like obesity, increasing healthcare expenditure and presence of major NASH players in the region.
- Whereas, Asia Pacific non-alcoholic steatohepatitis market in expected to be the fastest growing segment of global NASH market owing to growing prevalence of NASH, advancing healthcare infrastructure and increasing investments from international NASH players in countries like China and India, having positive impact on diagnostic advancements in the region. The Asia Pacific non-alcoholic steatohepatitis market is further divided into six regions on the basis of geographical operations, namely, China, India, Japan, Australia, South Korea and Rest of Asia Pacific, where China non-alcoholic steatohepatitis market held the largest share in Asia Pacific non-alcoholic steatohepatitis market.
For more information about this report visit https://www.researchandmarkets.com/r/5i24wb
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
